socalTECH
NOVEMBER 2, 2018
Carlsbad-based DNAe says it has developed a new, diagnostic platform that uses semiconductor DMA to help in treating antimicrobial resistant infections. million contract with the U.S. government to developing DNA sequencing technology to help physicians by providing rapid diagnosis of antimicrobial resistant infections and influenza.
TechCrunch LA
MARCH 27, 2020
Consumers now have their first chance to sample the wares of a short-form streaming service — and it’s not Quibi. Shows on the platform at launch include a gameplay-focused series built around the augmented reality game, Ingress , developed by Niantic , the game studio behind the massive AR hit Pokemon Go.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
NOVEMBER 6, 2017
The San Diego company, founded a decade ago on 3D bio-printing technology developed by the University of Missouri’s Gabor Forgacs, appeared to be gaining momentum on multiple fronts. In a related initiative, Organovo began moving to develop larger “patches” of 3D-printed human liver tissue for potential use in transplantation in.
InfoChachkie
MAY 9, 2011
In many cases, agreements crafted by BDC lawyers resemble ConTraps rather than mutually beneficial contracts. This series describes how entrepreneurs can craft company-changing agreements with BDCs, while avoiding Kiss of Death contract provisions. Part III addresses these contract traps: World-wide Distribution. Free Pilots.
Startup Professionals Musings
OCTOBER 30, 2021
Based on a small sample of household names from Bill Gates to Mark Zuckerberg, he is an optimist. Here is some data from Wikipedia: Microsoft – Bill Gates founded Microsoft in 1975, to develop and sell BASIC interpreters for the Altair 8800.
InfoChachkie
MAY 9, 2011
In many cases, agreements crafted by BDC lawyers resemble ConTraps rather than mutually beneficial contracts. This series describes how entrepreneurs can craft company-changing agreements with BDCs, while avoiding Kiss of Death contract provisions. Part III addresses these contract traps: World-wide Distribution. Free Pilots.
Xconomy
SEPTEMBER 9, 2016
It’s been almost two years since Organovo (NYSE: ONVO ) created a new business—using its bio-printing technology to create 3-D samples of living human liver tissue for use in testing the toxicity of pre-clinical drug candidates. We look at ourselves as a human tissues company…We’ll test your compound in our lab as a service.”.
Expert insights. Personalized for you.
133 
Let's personalize your content